European entrepreneurs call for more capital as funding gap persists
Executive summary: European entrepreneurs are urging capital markets to increase funding for startups, asking when investors will step up to meet rising demand. Access to capital is critical for scaling innovation; a prolonged funding gap could hinder EU competitiveness and slow economic growth.
Who is involved: European startup founders, venture capital firms, and EU policymakers focused on innovation and financing.
Likely next: Expect heightened VC activity, possible policy incentives, or new funding initiatives targeting early‑stage European companies within the next quarter.
European startup founders are increasingly vocal about the need for greater venture capital and public market support to scale their innovations. The article questions when investors will respond to this demand, highlighting a potential mismatch between entrepreneurial activity and capital availability. If capital does not increase, EU startups may face slower growth compared to peers in the US or Asia. The piece underscores the importance of aligning funding sources with the continent’s innovation agenda.
Timeline
- — Europe’s entrepreneurs are pushing. When will the capital markets pull? (Sifted — EU startups)
- — The people set to influence tech policy in Burnham’s Britain (Sifted — EU startups)
- — New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease (PR Newswire)
- — Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB (PR Newswire)
- — STL gewinnt Patentstreit in Europa eindeutig und bekräftigt sein Engagement für den Schutz seiner Innovationen und seines geistigen Eigentums (PR Newswire)
Sources
- Europe’s entrepreneurs are pushing. When will the capital markets pull? — Sifted — EU startups
- The people set to influence tech policy in Burnham’s Britain — Sifted — EU startups
- Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB — PR Newswire
- STL gewinnt Patentstreit in Europa eindeutig und bekräftigt sein Engagement für den Schutz seiner Innovationen und seines geistigen Eigentums — PR Newswire
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease — PR Newswire